Conflict of interest: C.J.F., S.H.I. and R.S.D. have worked with 3M Pharmaceuticals on separate but related studies. C.J.F. had full access to all the data in the study and had final responsibility for the decision to submit for publication.
A pilot study of treatment of lentigo maligna with 5% imiquimod cream
Article first published online: 6 AUG 2004
British Journal of Dermatology
Volume 151, Issue 2, pages 485–488, August 2004
How to Cite
Fleming, C.J., Bryden, A.M., Evans, A., Dawe, R.S. and Ibbotson, S.H. (2004), A pilot study of treatment of lentigo maligna with 5% imiquimod cream. British Journal of Dermatology, 151: 485–488. doi: 10.1111/j.1365-2133.2004.05983.x
- Issue published online: 6 AUG 2004
- Article first published online: 6 AUG 2004
- Accepted for publication 10 December 2003
- lentigo maligna;
- lentigo maligna melanoma;
- skin cancer
Background Lentigo maligna (LM) is an in situ form of malignant melanoma, and surgical excision is often unsatisfactory. Imiquimod cream is an immune response modifier and induces a predominantly T-helper 1 type response.
Objectives Assessment of histological and clinical response of surgically resectable LM after treatment with 5% imiquimod cream.
Methods Six patients with LM were treated with 5% imiquimod cream daily for 6 weeks. The whole site of the original lesion was then excised. Clinical and histological and appearances were measured using clinical response and histological grading scores.
Results Complete or almost complete clearance of pigmentation with minimal residual histological evidence of LM was observed in four patients, one patient showed no clinical or histological improvement, and the remaining patient had almost no residual pigmentation clinically after treatment yet histopathological changes remained as severe as before treatment.
Conclusions Topical imiquimod cream merits further investigation as a new therapy for LM.